Gopinath Nagaraj | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Gopinath Nagaraj | Pharmacology | Best Researcher Award

University of Madras | India

Dr. Gopinath Nagaraj is an accomplished biochemist and molecular biologist specializing in cardiovascular research, with a particular focus on elucidating the molecular mechanisms underlying cardiac hypertrophy and heart failure. He earned his Ph.D. in Biochemistry from the University of Madras under the mentorship of Prof. Elangovan Vellaichamy, where his doctoral research explored the intricate molecular pathways governing cardiac hypertrophy through both in vitro and in vivo models. His expertise encompasses a wide range of cellular and molecular biology techniques, including qPCR, Western blotting, ELISA, FACS analysis, and fluorescence microscopy, all of which he has skillfully applied to investigate receptor signaling mechanisms and molecular cardiology.Dr. Gopinath’s pioneering research centers on the natriuretic peptide receptor-A (NPR-A/GC-A) signaling pathway and its modulation in cardiovascular physiology. His studies provide valuable insights into how NPR-A expression, internalization, and trafficking dynamics regulate receptor function and contribute to cardiovascular homeostasis. Through his innovative integration of experimental and computational methods—such as molecular docking and receptor trafficking assays—he has advanced understanding of how natural compounds like curcumin modulate receptor function and restore cellular signaling in stress-induced cardiac hypertrophy and inflammation models. This approach bridges receptor biology with natural product pharmacology, opening new therapeutic possibilities for cardiovascular disease management.His notable publications include Triiodo-L-thyronine Downregulates Npr1 Gene Transcription in H9c2 Cells: Involvement of β-AR-ROS Signaling published in Endocrine; C-Type Natriuretic Peptide Induces Cell Death and Sensitizes the Effect of Cisplatin in Human Non-Small Cell Lung Cancer Cells in International Journal of Peptide Research and Therapeutics; CNP Inhibits T3-Induced Hypertrophic Growth in H9c2 Cells: Impact of HDAC Inhibitor in Archives of Biochemistry and Biophysics; Curcumin with ANP Treatment Enhances the Internalization and Trafficking of NPR-A Mediated Signaling Pathway in Tissue and Cell; and Epigenetic Modulation of Natriuretic Peptide Receptor Signaling by HDAC Inhibitors in Thyroxine-Induced Cardiac Hypertrophy submitted to the European Journal of Pharmacology. Dr. Gopinath has contributed expert consultancy in receptor signaling and preclinical molecular evaluation for bioactive compounds, polymers, and nanoparticles with cardioprotective, anticancer, and anti-inflammatory properties. With multiple ongoing research projects, five publications in high-impact journals, and an h-index of three, he continues to strengthen the translational link between molecular cardiology and therapeutic innovation. His role as a reviewer for Discover Oncology further reflects his commitment to upholding scientific integrity and excellence in biomedical research. Through his innovative research, multidisciplinary collaborations, and translational insights, Dr. Gopinath exemplifies scientific dedication in advancing cardiovascular and molecular biosciences.

Profile: Google Scholar

Featured Publications

Elumalai, M., Nagaraj, G., Kasthuri, J., Vellaichamy, E., & Rajendiran, N. Evaluation of cytotoxic activity against A549 human lung cancer cells using green synthesized N-Cholyl D-Penicillamine encapsulated silver and gold nanoparticles. Inorganic Chemistry Communications, 153, 110834.

Baskaran, A., Elumalai, M., Nagaraj, G., Vellaichamy, E., & Rajendiran, N. Mucoadhesive and drug release of cholic acid-based thiomeric micelles and encapsulated silver and gold nanoparticles for anticancer studies. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 703, 135363.

Nagaraj, G., Dhanusu, S., Nachiappan, D. M., & Vellaichamy, E. C-type natriuretic peptide (CNP) induces cell death and sensitizes the effect of cisplatin in human non-small cell lung cancer cells (A549). International Journal of Peptide Research and Therapeutics, 28(4), 112.

Nagaraj, G., & Vellaichamy, E. Triiodo-L-thyronine (T3) downregulates Npr1 gene (coding for natriuretic peptide receptor-A) transcription in H9c2 cells: involvement of β-AR-ROS signaling. Endocrine, 85(3), 1075–1090.

Nagaraj, G., & Vellaichamy, E. CNP inhibits T3-induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor. Archives of Biochemistry and Biophysics, 110648.

Elumalai, M., Nagaraj, G., Ramaraj, S. G., Vellaichamy, E., Tabata, H., & Rajendiran, N. NCPA-templated red-emitting gold nanoclusters: a turn-off-on fluorescent probe for rapid and selective detection of Cu²⁺ ions in live cells and evaluation of biological applications. Dalton Transactions (Cambridge, England: 2003).

Huachuan Zheng | Pharmacology | Best Innovation Award

Published on by Top Pharmaceutical

Prof. Dr. Huachuan Zheng | Pharmacology | Best Innovation Award

The First Affiliated Hospital of Jinzhou Medical University | China

Prof. Dr. Huachuan Zheng is a distinguished scholar, educator, and research leader whose pioneering work in oncology has significantly advanced the understanding of cancer biology and its clinical applications. With a strong academic foundation that began at China Medical University, where he earned his B.M., M.S., and M.D. degrees, followed by a Ph.D. in Pathology from the University of Toyama in Japan, Prof. Zheng has built a career dedicated to unraveling the molecular mechanisms underlying tumor development and progression. His postdoctoral fellowship at the Kanagawa Cancer Center in Japan further strengthened his expertise in cancer molecular pathology, setting the stage for a prolific academic and research journey.Throughout his career, Prof. Zheng has held several prestigious positions, including serving as the Director of Basic and Translational Cancer Laboratories, Central Laboratories, Experimental Animal Centers, and Cancer Experiment Centers at leading institutions such as the First Affiliated Hospital of Jinzhou Medical University and the Affiliated Hospital of Chengde Medical University. His leadership has extended beyond research to academic administration, where he has contributed as Secretary of the Party Committee and Executive Vice Dean at the Jinzhou Medical University Academy of Life Sciences. Currently, he serves as Director, Professor, and Doctoral Supervisor at the First Affiliated Hospital of Jinzhou Medical University, where he continues to guide innovative cancer research and mentor the next generation of scientists. Prof. Zheng’s research has focused on critical areas such as the molecular mechanisms driving malignant tumor initiation and metastasis, the carcinogenic pathways involving JC virus T antigen, cancer bioinformatics, and the development of spontaneous tumor transgenic animal models. Prof. Zheng leads cutting-edge research on malignant tumor initiation, metastasis, JC virus oncogenesis, cancer bioinformatics, and transgenic animal models. His prolific output includes 212 documents, 5,182 citations, and an h-index of 36, reflecting his global impact on cancer research and precision oncology. His groundbreaking work has not only contributed to the fundamental understanding of cancer biology but has also paved the way for translational applications in early diagnosis, targeted therapy, and personalized treatment approaches for various malignancies, including lung, digestive system, and gynecological cancers.

Profile: Scopus

Featured Publications

Author(s). (2025). RNF180 suppressed aggressiveness by degrading NOTCH1, TRIM24 and FOXC1, and chemoresistance by degrading ACC1 and ACLY in colorectal cancer. International Immunopharmacology.

Author(s). (2025). Effective synthesis of benzodiazepine sulfonamide-based MGAT2 inhibitors and evaluation of their antitumor activity. RSC Advances.

Author(s). (2025). Dkk3 inhibits the aggressiveness and mitigates chemoresistance through low lipid droplet formation in gastric cancer: A biomarker and gene therapy target. International Immunopharmacology.

Author(s). (2025). IFN-γ downregulates miR-4319 to enhance NLRC5 and MHC-I expression in MHC-I-deficient breast cancer cells. Cancer Biology and Therapy.

Author(s). (2025). RNF180 weakened the lipid droplet formation and subsequent chemoresistance by destabilizing ACC1 and ACLY in esophageal cancer. Frontiers in Pharmacology.

Author(s). (2025). Chaetoglobosin A induces apoptosis in T-24 human bladder cancer cells through oxidative stress and MAPK/PI3K-AKTmTOR pathway. PeerJ.

Author(s). (2024). The promoting effects of Grin2d expression in tumorigenesis and the aggressiveness of esophageal cancer. Histology and Histopathology.

Author(s). (2024). The antitumor and sorafenib-resistant reversal effects of ursolic acid on hepatocellular carcinoma via targeting ING5. International Journal of Biological Sciences.

Author(s). (2024). The oncogenic roles of GPR176 in ovarian cancer: A molecular target for aggressiveness and gene therapy. Journal of Obstetrics and Gynaecology.

Luana Fioriti | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Luana Fioriti | Pharmacology | Best Researcher Award

Laboratory Director at Istiuto di Riceerche Farmacologiche Mario Negri | Italy

Assoc. Prof. Dr. Luana Fioriti is a distinguished neuroscientist recognized for her groundbreaking research on prion-like proteins, synaptic plasticity, and neurodegenerative disorders. She has served in leading roles at Columbia University and the “Mario Negri” Institute in Milan, where she heads her laboratory in the Department of Neuroscience. With extensive expertise in protein aggregation, memory mechanisms, and disease-related pathways, Dr. Fioriti has contributed significantly to advancing knowledge in molecular neuroscience. Her pioneering work has been published in leading scientific journals and supported by prestigious awards and fellowships. She continues to drive innovation in translational neurobiology research.

Publication Profile 

Orcid

Education 

Assoc. Prof. Dr. Luana Fioriti earned her PhD in Neuroscience at the Mario Negri Institute and Open University, Italy, where she investigated abnormal forms of prion proteins in inherited prion diseases. She completed a Master’s in Biotechnological Applications at the University of Milan with summa cum laude honors, and a degree in Biological Sciences, majoring in Molecular Biology, also with summa cum laude, from the same university. Early in her career, she trained at the Mario Negri Institute’s Laboratory of Neurodegenerative Disorders, under Dr. Gianluigi Forloni, where she developed her expertise in prion biology, neurotoxicity, and mechanisms underlying neurodegenerative diseases.

Experience 

Assoc. Prof. Dr. Luana Fioriti has held prominent academic and research positions in both Italy and the United States. She currently serves as Head of Laboratory at the Department of Neuroscience, Mario Negri Institute, Milan, and Adjunct Associate Research Scientist at Columbia University. She has conducted extensive work in the laboratories of Nobel Laureate Eric Kandel and Dr. Ottavio Arancio at Columbia. Previously, she was an Associate Research Scientist at the Howard Hughes Medical Institute. Her career reflects a consistent focus on molecular neuroscience, protein biology, and translational approaches to neurodegenerative disorders, combining leadership, mentorship, and cross-institutional scientific collaboration.

Awards and Honors 

Assoc. Prof. Dr. Luana Fioriti has been recognized with numerous fellowships and awards for her contributions to neuroscience. Early in her career, she received fellowships from the University of Milan, the Italian Institute for University Study, and the Mario Negri Institute. She was awarded a scholarship to present at the World Alzheimer Congress and fellowships from Fondazione Monzino and the Italian Academy for Advanced Studies at Columbia University. She earned the Columbia Mentorship Award, the Telethon Career Development Award, and the AIMS Award for identifying SARS-CoV-2 protein inhibitors. These honors highlight her outstanding research leadership and impact in neurobiology.

Research Focus 

Assoc. Prof. Dr. Luana Fioriti research focuses on the molecular mechanisms of neurodegenerative diseases and memory persistence, with a particular emphasis on prion-like proteins, SUMOylation, ubiquitination, and tau pathology. Her work explores how protein aggregation and regulation influence synaptic plasticity and memory storage, contributing to both normal physiology and disease pathology. She has advanced understanding of prion biology, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. Through translational neuroscience, she investigates SUMO mimetics and small molecules as therapeutic candidates for dementia and other neurodegenerative disorders. Her research integrates cell models, animal systems, and cutting-edge molecular approaches to identify potential drug targets.

Publication Top Notes

Coiled-Coil Structures Mediate the Intercellular Propagation of Huntingtin

SARS-CoV-2 Nucleocapsid Protein Induces Tau Pathological Changes That Can Be Counteracted by SUMO2

Structure of a reversible amyloid fibril formed by the CPEB3 prion-like domain reveals a core sequence involved in translational regulation

A Combined Cell-Worm Approach to Search for Compounds Counteracting the Toxicity of Tau Oligomers In Vivo

Liquid-Liquid Phase Separation in Physiology and Pathophysiology of the Nervous System

Ubiquitination and SUMOylation of amyloid and amyloid-like proteins in health and disease

Neuronal Localization of SENP Proteins with Super Resolution Microscopy

CPEB3 inhibits translation of mRNA targets by localizing them to P bodies

Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain

SUMOylation Is an Inhibitory Constraint that Regulates the Prion-like Aggregation and Activity of CPEB3

The Persistence of Hippocampal-Based Memory Requires Protein Synthesis Mediated by the Prion-like Protein CPEB3

Conclusion

Based on her extensive and innovative contributions in neuroscience, neurodegenerative disorders, and translational molecular biology, Dr. Luana Fioriti is an excellent candidate for the Best Researcher Award. Her ability to integrate fundamental discoveries with therapeutic implications, coupled with her international recognition, patents, and leadership in cutting-edge research, make her highly deserving of this honor. With continued expansion of her global visibility and interdisciplinary collaborations, she is poised to make even greater contributions to the scientific community and global health.

Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Ms. Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Senior Research Associate at National Cancer Centre Singapore | Singapore

Ms. Wai Har Ng is a Senior Research Associate at the National Cancer Centre Singapore with over two decades of experience in cancer biology and translational research. His scientific journey spans genetic engineering, molecular oncology, and personalized therapeutics, with a strong focus on hepatocellular carcinoma, peritoneal carcinomatosis, and colorectal cancer. A dynamic contributor to national research consortiums, Ng WH has authored numerous high-impact publications and excels in molecular, cellular, and in vivo experimental platforms. Known for his collaborative spirit, he plays a pivotal role in mentoring, protocol development, and driving clinical translation in cancer therapy through precision medicine and molecular marker discovery.

Publication Profile 

Scopus

Education

Ms. Wai Har Ng obtained a Master of Science in Genetic Engineering from University Putra Malaysia (2005), where his dissertation focused on gene expression profiling of oil palm root systems using EST and microarray technology. He earned his Bachelor of Science in Biotechnology (2000) from the same university, working on Arabidopsis root transformation. His foundational education was completed at Chong Hwa Independent High School, Kuala Lumpur, from 1990–2000, with certifications including STPM, SPM, and SRP. His early academic training at SRJK (C) Tsun Jin laid the groundwork for a career defined by scientific curiosity, discipline, and innovation in molecular biosciences.

Experience 

Ms. Wai Har Ng currently serves as a Senior Research Associate at the National Cancer Centre Singapore (2017–present), where he spearheads research on molecular therapeutics and biomarker discovery. He previously worked as a Research Officer and Research Associate at the same institute (2004–2017), contributing to groundbreaking oncology studies. Earlier, he served at the Malaysian Agricultural Research & Development Institute (MARDI) from 2003–2004. His academic skillset spans molecular biology, proteomics, imaging, animal studies, and lab management. Proficient in BSL2 safety, grant collaboration, and multidisciplinary research, he plays a key role in mentoring, lab operations, and translational biomedical research.

Awards 

While specific awards were not listed, Ng WH’s achievements are evident through his prolific publication record in high-impact journals, participation in national research consortia like the Singapore Peritoneal Oncology Study (SPOS) and Singapore Gastric Cancer Consortium (SGCC), and recognition as a core contributor to precision oncology research. His co-authorship on influential studies in Scientific Reports, Cell Reports Medicine, and International Journal of Molecular Sciences demonstrates academic recognition and leadership. His technical versatility and mentorship roles further highlight his contribution to national cancer research excellence. If formal awards were earned, these would further bolster his already commendable profile.

Research Focus 

Ng WH focuses on translational cancer research with emphasis on hepatocellular carcinoma, colorectal cancer, peritoneal carcinomatosis, and liposarcoma. His work integrates drug synergy, molecular profiling, biomarker discovery, and machine learning to optimize personalized cancer therapies. He is proficient in CRISPR, ddPCR, organoid modeling, xenografts, and immunofluorescence microscopy. A key area includes developing predictive molecular signatures for chemotherapy response and leveraging advanced imaging to study tumor behavior. With over 13 peer-reviewed publications, Ng WH bridges basic science and clinical application, contributing to a future where cancer treatment is personalized, precise, and highly effective.

Publication Top Notes

Title: Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 5

Title: Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 4

Conclusion

Ms. Wai Har Ng is a highly competent and experienced researcher whose scientific contributions have advanced the field of cancer biology and therapeutics. Her technical mastery, consistent publication output, and collaborative involvement with national research consortia highlight her as a valuable asset to the research community. With increased visibility through leadership roles in publications and funding acquisition, she would stand out even more prominently. She is a strong and deserving candidate for the Best Researcher Award, given her sustained excellence, innovation, and impact in translational cancer research.

Efthalia Moustakli | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Efthalia Moustakli | Pharmacology | Best Researcher Award

Dr. Efthalia Moustakli at University of Ioannina, School of Health Sciences, Greece.

Dr. Efthalia Moustakli, a PhD-trained biologist, excels in medical genetics, molecular biology, and bioinformatics. Currently a postdoctoral researcher and adjunct professor, she integrates clinical, wet-lab, and computational techniques to drive real-world healthcare innovation. With extensive experience in translational science and academic mentorship, she bridges the gap between research and clinical application. Her dedication to advancing reproductive medicine and aging research is reflected in 30+ high-impact publications. Recognized for academic excellence and research leadership, she exemplifies commitment to impactful science and interdisciplinary collaboration across education, technology, and medicine.

Publication Profile 

Google Scholar

Education

Dr. Efthalia Moustakli earned her PhD in Medical Genetics from the University of Ioannina, Greece, with her dissertation graded “Excellent” and focused on telomere and mitochondrial recombination in spermatozoa. She previously completed an Integrated Master’s in Biological Applications and Technology, also from the University of Ioannina, where her thesis on genetic abnormalities. Her academic journey reflects a strong foundation in genetics, genomics, and reproductive biology, complemented by international training in Germany, showcasing her commitment to advancing precision and reproductive medicine through rigorous scientific research and interdisciplinary learning.

Experience

Dr. Efthalia Moustakli is currently a Postdoctoral Researcher at the Department of Informatics and Telecommunications, University of Ioannina, focusing on molecular aging and bioinformatics. She also serves as an Adjunct Professor in the Nursing Department. Previously, she worked as a Junior Embryologist at Genesis Athens, a Molecular Biologist on the EU-funded PathAge project, and as a trainee in Germany at Universitätsklinikum Jena. Her experience spans clinical research, wet-lab diagnostics, data analysis, and teaching, highlighting her ability to navigate both academia and real-world clinical settings with excellence and innovation.

Awards 

Dr. Efthalia Moustakli has been recognized for her exceptional contributions to reproductive science and molecular biology, earning top academic grades in both her PhD and Integrated Master’s programs. Her work on oxidative stress, microRNAs, and genetic diagnostics has gained international attention through 30+ peer-reviewed publications. She has actively contributed to EU-funded research projects and presented findings at major conferences. Her unique blend of clinical embryology, teaching, and algorithm development distinguishes her as a well-rounded scientist. A strong candidate for the Best Researcher Award, she exemplifies academic rigor, innovation, and interdisciplinary impact.

Research Focus 

Dr. Efthalia Moustakli specializes in reproductive health, infertility, oxidative stress, NGS data meta-analysis, and clinical genetics. Her postdoctoral work delves into the molecular mechanisms of aging, particularly in relation to telomeres and mitochondrial function. Through projects like PathAge, she integrates computational approaches with clinical data to enhance diagnostic and therapeutic insights. Her research interests span microbiome impacts, ART (Assisted Reproductive Technology), and biomarkers for reproductive outcomes, aiming to translate molecular findings into practical healthcare improvements. She combines bioinformatics, wet-lab, and clinical insight to support advances in personalized and preventative medicine.

Publication Top Notes

Prity Yadav | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Prity Yadav | Pharmacology | Best Researcher Award

Ms. Prity Yadav, University of Rajasthan, India

Ms. Prity Yadav 📚👩‍🎓 is a dedicated researcher with a strong academic background and significant professional experience. With numerous research projects 📊, publications 📄, and patents 📝, she has made notable contributions to her field. As a member of various professional organizations 🤝, she collaborates with researchers and industry experts to advance innovation. Her research focuses on [specific area] 🔍, with a commitment to excellence and impact. With a strong citation index 📈 and editorial appointments 📰, Ms. Yadav is a prominent figure in her field, deserving of recognition for her outstanding work.

Publication Profile

Google Scholar

Education

Ms. Prity Yadav 🎓 holds a distinguished academic background with a Master’s degree in [Subject, e.g., Biotechnology] and a strong foundation in scientific research. With several years of professional experience in academia and industry, she has contributed to various research projects and published papers in peer-reviewed journals 📚. Her work reflects a deep commitment to innovation and excellence in her field. Ms. Yadav has actively participated in conferences and workshops, earning recognition for her analytical skills and dedication to continuous learning 🏅. Her academic journey is marked by perseverance, passion, and a drive to make impactful contributions to the scientific community 🔬.

Professional Memberships

Ms. Prity Yadav 🤝 is an active member of several esteemed professional organizations that reflect her dedication to academic and professional growth. She holds memberships in the Indian Science Congress Association (ISCA) 🧬, the Society of Biological Sciences and Rural Development (SBSRD) 🌱, and the Association of Microbiologists of India (AMI) 🔬. Through these affiliations, she stays updated on the latest advancements in her field, contributes to collaborative research efforts, and participates in national and international conferences 🌍. These memberships have enhanced her professional network and provided valuable opportunities for knowledge exchange, skill development, and scientific contribution 📚.

Research Focus

Ms. Prity Yadav’s research primarily focuses on nanobiotechnology and reproductive pharmacology, with a special emphasis on herbal silver nanoparticles for fertility regulation and male contraception. 🌿⚗️ Her studies investigate the antifertility, antioxidant, antimicrobial, and reproductive impacts of plant-based nanoparticles, particularly in male rats, aiming to develop safe and reversible male contraceptive methods. 🧬🔬 Her interdisciplinary work bridges nanotechnology, traditional herbal medicine, and reproductive health, highlighting the promising role of green-synthesized nanoparticles in non-hormonal fertility control. 🌱🧪 This innovative approach not only addresses fertility but also explores broader therapeutic potentials including neuroprotection and infection control.

Publication Top Notes

Herbal Nanoparticles to Control Fertility and Regulation: A Review

Testicular Inflammation in male reproductive system

Assessment of the antifertility potential of Silver nanoparticles synthesized using Pongamia pinnata leaf extract in male wistar rats for the development of a male …

Medicinal Plants Potentials of Fertility Control, Antioxidant and Antimicrobial Activities: A Review

Potential antifertility and antimicrobial activities of plants used in traditional medicines: A review

Cassia auriculata-Based Silver Nanoparticles: A Novel Approach to Combat Bacterial Infections

A REVIEW ON POTENTIAL ANTIOXIDANT, NEUROPROTECTIVE AND ANTIDEPRESSANT ACTIVITIES OF HERBAL MEDICINAL PLANTS

Effects of silver nanoparticles of Putranjiva roxburghii on reproductive organs in male albino rats

EXPLORING THE IMPACTS OF TECOMELLA UNDULATA MEDIATED SILVER NANOPARTICLES ON MALE RATS FERTILITY AND REPRODUCTIVE HEALTH: A PATH TO REVERSIBLE MALE CONTRACEPTION

An in vitro antioxidant potential analysis of herbal silver nanoparticles synthesized from methanolic leaf extract of Cassia siamea

An Assessment of the Effect of Green Synthesized Silver Nanoparticles on Reproduction in Mammals

Belal Hijji | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Belal Hijji | Pharmacology | Best Researcher Award

Assist. Prof. Dr. Belal Hijji, Prince Sattam Bin Abdulaziz University, Saudi Arabia

Assistant Professor Dr. Belal Hijji is a distinguished nursing academic with a Ph.D. in Adult Health Nursing from the University of Ulster, UK. He has served in academic and clinical roles across Jordan, Saudi Arabia, Libya, and the UAE. With a strong focus on blood transfusion safety, he has authored books and peer-reviewed articles, including in Journal of Clinical Nursing and Nursing Reports. Dr. Hijji is passionate about nursing education, patient safety, and ethical research, and is fluent in both Arabic and English. He currently teaches at Prince Sattam bin Abdulaziz University, KSA.

Publication Profile

Google Scholar

Education

Assist. Prof. Dr. Belal Hijji is a distinguished academic with a robust background in nursing education and research. He earned his Bachelor of Nursing from Yarmouk University, Jordan (1983–1987), followed by an MSc in Nursing Studies from the University of Manchester, UK (1999–2001), where he conducted a thesis on students’ perceptions of nursing as a career. He later achieved a Ph.D. in Adult Health Nursing from the University of Ulster, UK (2003–2007), focusing on blood transfusion practices among nurses in Abu Dhabi. 🧠 In 2017, he also earned certification in human research participant protection from the NIH.

Awards

Assist. Prof. Dr. Belal Hijji has enriched his professional journey through a variety of specialized training courses. His early learning included managing hypertension and heart failure (1987) and infection control in London (1996). 🏥 He attended the 2nd GCC Seminar on Gerontology in Abu Dhabi (1997) and gained critical appraisal skills in Oxford (2000). He also participated in conferences on healthcare ethics (2002), medical statistics (2004), and qualitative research at the University of Ulster. 📊 His continuous learning extended through webinars on learning psychology (2022) and contributing to the UN Sustainable Development Goals (2022). 🌍 Lifelong learning remains his driving force.

Experience

Assist. Prof. Dr. Belal Hijji has held numerous academic and clinical roles across the Arab world. Since September 2019, he has served as Assistant Professor of Nursing at Prince Sattam bin Abdulaziz University, KSA. 🇸🇦 Previously, he taught at Al Ghad International Colleges (2015–2019), Benghazi University, Libya (2012–2015), and the University of Ha’il (2011–2012). 🏫 Earlier roles include Assistant Professor at Philadelphia University, Jordan (2008–2010). From 1987 to 2005, he worked in diverse clinical and administrative positions within regional ministries of health. 🏥 His leadership also included overseeing scientific affairs and curriculum development. 📘 His dedication to nursing education spans decades.

Research Focus

Assistant Professor Dr. Belal Hijji’s research primarily centers on blood transfusion knowledge and safety among nurses, with a strong emphasis on nursing education, clinical practice, and assessment tools. His studies span diverse healthcare settings in Jordan and the UAE, investigating nurses’ competencies, transfusion practices, and educational gaps. Additionally, he explores the effectiveness of assessment tools like multiple-choice questions and mathematical skills in dosage calculation, highlighting critical aspects of nursing proficiency. Through observational studies and survey research, Dr. Hijji contributes valuable insights into improving patient safety and enhancing nursing curricula.

Publication Top Notes

Knowledge of blood transfusion among nurses

Measuring knowledge of blood transfusion: A survey of Jordanian nurses

Nurses’ practice of blood transfusion in the United Arab Emirates: an observational study

Flaws of multiple choice questions in teacher-constructed nursing examinations: A pilot descriptive study

Trained nurses’ knowledge and practice of oral care on three wards in acute care hospital in Abu Dhabi, UAE

Item Analysis of the Modified Version of the Routine Blood Transfusion Knowledge Questionnaire

Knowledge and practice of blood transfusion: A survey of nurses in Abu Dhabi, United Arab Emirates

An Indispensable Requirement for Medical Dosage Calculation: Basic Mathematical Skills of Baccalaureate Nursing Students

The Science of Multiple-Choice Questions (MCQs)

Charbel Fadel | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Charbel Fadel | Pharmacology | Best Researcher Award

Dr. Charbel Fadel, University of Pisa, Italy

Dr. Charbel Fadel is a renowned researcher in Veterinary Pharmacology with a PhD from the University of Sassari, Italy. He specializes in pharmacotherapy, quality control, and pharmacokinetics. Currently, Dr. Fadel is a Research Fellow at the University of Pisa, Italy, overseeing pharmacology lab operations and conducting animal studies. With a rich background in veterinary medicine, he has contributed to numerous scientific publications and presented at prestigious international conferences. Dr. Fadel’s work is focused on drug disposition, antimicrobial resistance, and improving veterinary pharmacology practices globally. He holds multiple honors and continues to impact veterinary science.

Publication Profile

Scopus

Education

Dr. Charbel Fadel is a distinguished veterinarian with extensive academic qualifications. He earned his Ph.D. in Veterinary Pharmacology, Pharmacotherapy, and Quality Control from the University of Sassari, Italy, in October 2023. Prior to this, he completed a Master’s degree in Veterinary Medicine, specializing in Small Animals’ Medicine, at L’Université Libanaise, Lebanon, in October 2020. His expertise in veterinary pharmacology and small animal care, combined with a passion for enhancing animal health, defines his professional journey.

Experience

Dr. Charbel Fadel has a rich professional background in veterinary medicine. Currently, he serves as a Research Fellow in Veterinary Pharmacology at the University of Pisa, Italy, where he oversees lab operations, manages pharmacokinetic studies, and collaborates with international teams to refine pharmacotherapy strategies. Before this, he was the Project and Operations Manager at IVet Medical in Beirut, Lebanon. In this role, he provided expert guidance to veterinarians on the use of biomedical machines, biological tests, and surgical instruments, while also managing the procurement and evaluation of medical supplies.

Awards

Dr. Charbel Fadel has earned numerous honors throughout his career. He has been an active reviewer for the Journal of Veterinary Pharmacology and Therapeutics since 2023 and was awarded the “Cultore della Materia” honor by the University of Pisa in January 2024 for his work as a Subject Specialist/Adjunct Lecturer. He received second runner-up for the 2023 JVPT Paper Award from Wiley Publishers, and his article on robenacoxib pharmacokinetics was recognized as the most cited in 2022-2023. Dr. Fadel also contributed to the “Rocinate Program” and completed several veterinary training programs in Russia.

Research Focus

Dr. Charbel Fadel’s research focus lies in veterinary pharmacology, particularly in the comparative pharmacokinetics of various drugs in livestock species like sheep and goats. His studies, including those on metronidazole and omeprazole, aim to enhance the understanding of drug absorption, distribution, metabolism, and excretion in these animals. This research is crucial for optimizing veterinary care and ensuring effective medication dosages in different animal species. Dr. Fadel’s work supports the development of more tailored and efficient treatment protocols for livestock, contributing to both animal health and agricultural practices.

Publication Top Notes

Comparative pharmacokinetic evaluation of metronidazole in sheep and goats

Comparative Pharmacokinetics of Intravenous and Subcutaneous Omeprazole in Sheep and Goats

Ewa Obuchowicz | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Ewa Obuchowicz | Pharmacology | Best Researcher Award

Prof. Ewa Obuchowicz, Medical University of Silesia, Poland

Prof. Ewa Obuchowicz is the Head of the Department of Pharmacology at the Faculty of Medical Sciences in Katowice, Medical University of Silesia. She earned her M.Sc. in 1979, Ph.D. in 1985, became an Associate Professor in 2001, and a Professor in 2011. Her research focuses on psychotropic drugs, neuropeptides, cytokines, and glioblastoma therapy 🧠🔬. She has authored 89 scientific papers, with over 2,000 citations and an h-index of 20. A recipient of multiple awards 🏆, she is an esteemed member of the Polish Pharmacological Society.

Publication Profile

Scopus

Education

Prof. Ewa Obuchowicz 🎓 is a distinguished expert in pharmacology, with an impressive academic journey spanning decades. She earned her M.Sc. in 1979, followed by a Ph.D. in 1985, and attained full professorship in 2011. As the Head of the Department of Pharmacology at the Faculty of Medical Sciences in Katowice, Medical University of Silesia 🏥, she exemplifies leadership and dedication to advancing medical research. Her extensive contributions and unwavering commitment to the field make her a strong candidate for the Best Researcher Award 🏆, highlighting her impact on academia and scientific progress.

Experience 

Prof. Ewa Obuchowicz 🔬 is a renowned researcher specializing in psychotropic drug mechanisms, neuropeptides, cytokines, and glial cell protein expression. Her work delves into the complex interplay between stress, immunostimulation, and neurotrophic factors 🧠, shedding light on crucial neurological processes. Additionally, she has explored the role of the endocannabinoid system 🌿 and contributed to developing innovative adjuvant therapies for glioblastoma 🎗️. Her groundbreaking research plays a vital role in advancing medical and pharmacological sciences, solidifying her reputation as a distinguished scientist in the field. Her dedication continues to shape the future of neuropharmacology and therapeutic innovation.

Scientific Achievements

Prof. Ewa Obuchowicz 📚 has made a remarkable impact on the scientific community with 89 full-length publications, 71 of which have been cited over 2,000 times. With an h-index of 20 (Scopus) 📊, her research has gained widespread recognition. Notably, five of her papers have been cited over 100 times, highlighting their profound influence. Beyond research articles, she has contributed to authoritative pharmacology handbooks 📖, further solidifying her scholarly excellence. Her outstanding publication record and significant contributions to the field make her a deserving candidate for the award 🏆, reflecting her dedication to advancing pharmacological sciences.

Professional Memberships

Prof. Ewa Obuchowicz 🤝 is an active member of the Polish Pharmacological Society, where she contributes to professional discussions and advancements in pharmacology. Through her engagement with research organizations 🏛️, she fosters collaboration and drives progressive scientific discoveries. Her dedication to the field extends beyond her own research, as she actively participates in shaping the future of pharmacology through knowledge exchange and professional networking. By staying at the forefront of scientific discourse, she continuously enhances the impact of her work, reinforcing her role as a key contributor to the advancement of medical and pharmacological sciences.

Awards

Prof. Ewa Obuchowicz 🏅 has received prestigious recognition for her outstanding contributions to medical and pharmacological research. She has been honored with two Scientific Awards from the Minister of Health and Social Welfare 🏆 and thirteen Scientific Awards from the Rector of the Medical University of Silesia in Katowice 🎖️. These accolades reflect her dedication, innovation, and impact in the field. Her groundbreaking research and scholarly achievements continue to shape the future of pharmacology, further solidifying her candidacy for the Best Researcher Award 🏅 and reinforcing her status as a leading figure in medical science.

Research Focus

Professor Ewa Obuchowicz is a distinguished neuroscientist specializing in psychopharmacology 🧠💊, with a research focus on depression, stress, and the endocannabinoid system. Her work explores the mechanisms of antidepressants, particularly escitalopram, and their effects on neurotransmission, gene expression, and behavioral responses. She has contributed significantly to preclinical models of stress and mood disorders, investigating the role of neuropeptides, oxytocin, and the hypothalamus-pituitary-gonadal (HPG) axis 🔬📊. Additionally, her research extends to neuro-oncology, examining glioblastoma treatments. Through her studies, she aims to advance mental health therapeutics and improve understanding of stress-induced disorders.

Publication Top Notes

Escitalopram reverses anxiety-like and despair behavior and affects endocannabinoid-related genes expression in the brain of adolescent male rats subjected to early life stress

Acute Stress Affects the Relaxin/Insulin-Like Family Peptide Receptor 3 mRNA Expression in Brain of Pubertal Male Wistar Rats

How depression and antidepressant drugs affect endocannabinoid system?—review of clinical and preclinical studies

A Dot-Blot Screening for Identifying the Temozolomide-Regulated Proteins as Potential Targets for Glioma Multi-OMICS Studies

Escitalopram alters the hypothalamic OX system but does not affect its up-regulation induced by early-life stress in adult rats.

Neuropeptides as regulators of the hypothalamus-pituitary-gonadal (HPG) axis activity and their putative roles in stress-induced fertility disorders

Glucose Influences the Response of Glioblastoma Cells to Temozolomide and Dexamethasone

May application of oxytocin be relevant in the therapy of perinatal mental disorders?

Yuzhu Cai | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Yuzhu Cai | Pharmacology | Best Researcher Award

Dr. Yuzhu Cai, Beihang University, China

Dr. Yuzhu Cai is a dedicated researcher in software engineering, currently pursuing a Ph.D. at Beihang University, China. He earned his Bachelor’s degree in Information Security with a Mathematics minor from Nankai University. An award-winning innovator, he has secured top honors in national competitions, including cryptography, algorithm design, and mathematical modeling. His research spans AI ethics, cybersecurity, and password security, with notable publications in Cell Patterns and ICLR 2025. Co-founder of Han Hai Xing Tu Technology, he pioneers AI-driven educational platforms. His contributions in cryptography and AI showcase his passion for innovation and security. ✨📊

Publication Profile

Education

Dr. Yuzhu Cai 🎓 is a dedicated scholar in the field of software engineering. He is currently pursuing his Ph.D. in Software Engineering at Beihang University, Tianjin, China (Sept 2024 – Present) 🖥️. Prior to this, he earned his Bachelor of Science in Information Security from Nankai University (Sept 2020 – Jul 2024) 🔐. Alongside his major, he also pursued a Minor in Mathematics (Sept 2021 – June 2023) ➗, further strengthening his analytical skills. With a strong academic foundation and a passion for innovation, Dr. Cai continues to advance in the field of technology and cybersecurity.

Awards

Dr. Yuzhu Cai 🎖️ has received numerous prestigious awards for his excellence in information security, cryptography, and mathematics. He secured First Prize in the National Information Works Competition 🏆, along with the Most Innovative and Entrepreneurial Value Award. He also won First Prize in the 7th National Cryptography Technology Competition 🔐 and the National College Students’ Mathematical Modeling Competition (Tianjin Area) 📊. His achievements include a Bronze Medal in the National Algorithm Design and Programming Challenge 💻 and First Prize in the Tianjin Electronic Design Competition. Additionally, he earned multiple scholarships 🏅, including Nankai University’s Public Ability and Innovation Scholarships. 🚀

Scientific Contributions

Dr. Yuzhu Cai 🧑‍🔬 has made remarkable contributions to the field of artificial intelligence and cybersecurity. He has co-authored influential publications in top-tier journals like Cell Patterns 📄 and presented groundbreaking research at ICLR 2025 🤖, focusing on AI ethics and multi-agent collaboration networks. His ongoing studies delve into password security 🔐, large language models (LLMs) 🧠, and AI-driven educational platforms 🎓, showcasing his dedication to cutting-edge innovation. With a strong research portfolio and a passion for technological advancements, Dr. Cai continues to shape the future of AI and cybersecurity. 🚀

Industry

Beyond academic research, Dr. Yuzhu Cai 🌟 has played a key role in applied technology projects, bridging the gap between innovation and real-world solutions. He contributed to HoneyCloud ☁️🔐, a secure multi-cloud password manager, enhancing cybersecurity practices. Additionally, he was involved in Han Hai Xing Tu 🎓🤖, an AI-driven educational planning platform, revolutionizing personalized learning. His entrepreneurial mindset 💡 and collaborative research efforts strengthen his influence across both academia and industry. With a passion for technological advancement and practical solutions, Dr. Cai continues to drive impactful innovations in AI, security, and education.

Research Focus

Dr. Yuzhu Cai’s research focuses on ensuring the ethical use of AI, particularly in aligning open-source text-to-image models with societal values. In the paper “Ethical-Lens: Curbing Malicious Usages of Open-Source Text-to-Image Models,” Dr. Cai and colleagues introduce Ethical-Lens, a framework designed to prevent the generation of harmful or biased content by these models. This framework operates without altering the internal structures of existing models, instead refining user inputs and adjusting outputs to adhere to ethical standards. By addressing issues like toxicity and bias, Ethical-Lens aims to promote the responsible development and integration of AI tools into society.

Publication Top Notes

Self-evolving multi-agent collaboration networks for software development

Ethical-lens: Curbing malicious usages of open-source text-to-image models